請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31619完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳建仁,楊泮池,簡國龍 | |
| dc.contributor.author | I-Shiow Jan | en |
| dc.contributor.author | 詹一秀 | zh_TW |
| dc.date.accessioned | 2021-06-13T03:15:59Z | - |
| dc.date.available | 2008-08-04 | |
| dc.date.copyright | 2006-08-04 | |
| dc.date.issued | 2006 | |
| dc.date.submitted | 2006-07-31 | |
| dc.identifier.citation | 1. Health and vital statistics. Department of Health, Taiwan, Republic of China Web Site. Available at: http://www.doh.gov.tw/EN/Webpage/index.aspx. [Accessed 3 August 2005].
2. Health and vital statistics. Department of Health, Taiwan, Republic of China Web Site. Available at: http://crs.cph.ntu.edu.tw/crs_c/annual.html. [Accessed 1 September 2005]. 3. Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294-9. 4. Yang SP, Luh KT, Kuo SH, et al. Chronological observation of epidemiological characteristics of lung cancer in Taiwan with etiological consideration-A 30-year consecutive study. Jpn J Clin Oncol 1984;14:7-19. 5. Luh KT, Chang DB. Primary lung cancer in Taiwan. J Formos Med Assoc 1992;91 (Suppl 1):S1-7. 6. Chen YC, Chen JH, Richard K, et al. Lung adenocarcinoma and human papillomavirus infection. Cancer 2004;101:1428-36. 7. Barnes DJ. The changing face of lung cancer. Chest 2004;126:1718-21. 8. Koo LC, Ho JH. Worldwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol 1990;19 Suppl 1:S14-23. 9. Lee LT, Lee WC, Lin RS, et al. Age-period-cohort analysis of lung cancer mortality in Taiwan, 1966-1990. Anticancer Res. 1994;14:673-76. 10. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis, Lung cancer 2001;31:139-48. 11. Yang P, Cerhan JR, Vierkan RA, et al. Adenocarcinoma of the lung is strongly associated with cigarette smoking: further evidence from a prospective study of women. Am J Epidemiol 2002;56:1114-22. 12. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210. 13. Hoffmann D, Djordjevic MV, Hoffmann I. The changing cigarette. Prev Med 1997;26:427-34. 14. Ger LP, Hsu WL, Chen KT, et al. Risk factors of lung cancer. J Formos Med Assoc. 1992;91 (Suppl 3):S222-31. 15. Bureau of Tobacco and Alcohol Monopoly. Alcohol consumption investigation in Taiwan Area. 1993. Taipei: Taiwan Provincial Government; 1994. 16. Environmental protection agency. Respiratory health effects of passive smoking: lung cancer and other disorders, EPA/600/6-90/006F. Washington, DC: EPA Office of Research and Development; 1992. 17. Behera D, Balamugesh T. Indoor air pollution as a risk factor for lung cancer in women. J Assoc Physicians India 2005;53:190-2. 18. Rachtan J. Smoking, passive smoking and lung cancer cell types among women in Poland. Lung Cancer 2002;35:129-36. 19. Rapiti E, Jindal SK, Gupta D, et al. Passive smoking and lung cancer in Chandigarh, India. Lung Cancer 1999;23:183-9. 20. Fontham ET, Correa P, Chen VW. Passive smoking and lung cancer. J La State Med Soc 1993;145:132-6. 21. Ger LP, Hsu WL, Chen KT, et al. Risk factors of lung cancer by histological category in Taiwan. Anticancer Res 1993;13:1491-500. 22. Woodward SD, Winstanley MH. Lung cancer and passive smoking at work: the Carroll case. Med J Aust 1990;153:682-4. 23. Wu AH, Henderson BE, Pike MC, et al. Smoking and other risk factors for lung cancer in women. J Natl Cancer Inst 1985;74:747-51. 24. Correa P, Pickle LW, Fontham E, et al. Passive smoking and lung cancer. Lancet 1983;2:595-7. 25. Wang SY, Hu YL, Wu YL, et al. A comparative study of the risk factors for lung cancer in Guangdong, China. Lung Cancer 1996;14 (Suppl 1):S99-105. 26. Wu AH, Fontham ET, Reynolds P, et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1995;141:1023-32. 27. Osann. Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease. Cancer Res 1991;51:4893-7. 28. Taggart DP, Gray CE, Bowman A, et al. Serum androgens and gonadotrophines in bronchial carcinoma. Resp Med 1993;87:455-60. 29. Behera D, Malik SK, Sharma BR, et al. Circulating hormones in lung cancer. Indian J Med Res 1984;79:636-40. 30. Lin P, Tsai Chang J, Ko JL, et al. Reduction of androgen receptor expression by benzo[a]pyrene and 7,8-dihydro-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in human lung cells. Biochem Pharmacol 2004;67:1523-30. 31. Taggary DP, Gray C, Davidson KG, et al. Low serum testosterone as an indicator of metastatic bronchial carcinoma. Thorax 1987;42:661-3. 32. Bhatavadekar JM, Patel DD, Chikhlikar PR, et al. Levels of circulating peptide and steroid hormones in men with lung cancer. Neoplasm 1994;41:101-3. 33. Blackman MR, Weintraub BD, Rosen SW, et al. Comparison of the effects of lung cancer, benign lung disease, and normal aging on pituitary-gonadal function in men. J Clin Endocrinol Metab 1988;66:88-95. 34. Zhou XD, Cai WQ, Cao HW. Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissue of male patients with lung cancer. Ai Zheng 2002;3:259-62. 35. Price, DK, Franks ME, Figg WD. Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism. J Urology 2004;171:S45-S49. 36. Noronha RFX, Goodall CM. Enhancement by testosterone of dimethlynitrosamine carcinogenesis in lung, liver and kidney of inbred NZR/Gd female rats. Carcinogenesis 1983;4:613-6. 37. Noronha RFX, Goodall CM. Enhancement of hepatic and renal tumorigenesis in thyroidectomized NZR/Gd rats treated with dimethylnitrosamine. J Surg Oncol 1976;8:539-50. 38. Kaiser U, Hofmann J, Schilli M, et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 1996;67:357-64. 39. Maasberg M, Rotsch M, Jaques G, et al. Androgen receptors, androgen-dependent proliferation, and 5α-reductase activity of small-cell lung cancer cell lines. Int J Cancer 1989;43:685-91. 40. Beattie CW, Hansen NW, Thomas PA. Steroid receptors in human lung cancer. Cancer Res 1985;45:4206-14. 41. Kobayashi S, Mizuno T, Tobioka N, et al. Sex steroid receptors in diverse human tumors. Gann 1982;73:439-45. 42. Wilson CM, McPhaul MJ. A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol 1996;120:51-7. 43. Hoque A, Albanes D, Lippman SM, et al. Molecular epidemiologic studies within the selenium and vitamin e cancer prevention trial (SELECT). Cancer Care Control 2001;12:627-33. 44. Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94:3320-3. 45. Latil AG, Azzouzi R, Cancel GS, et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathway. Cancer 2001;92:1130-7. 46. Beilin J, Harewood L, Frydenberg M, et al. A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects. Cancer 2001;92:941-9. 47. Chamberlain NL, Driver E, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-6. 48. Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet 1995;4:523-7. 49. Yu MW, Cheng SW, Lin MW, et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 2000;92:2023-8. 50. Brentano ST, Picado-LeonardMellon SH, Miller WL. Tissue-specific cyclic adenosine 3’, 5’- monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells. Mol Endocrinol 1990;4:1972-1979. 51. Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Human Mol Genet 1994;3:1873-1876. 52. Lunn RM, Bell DA, Mohler JL et al. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20:1727-31. 53. Allen NE, Forrest MS, Key TJ. The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidem Biomar 2001;10:185-9. 54. Yamada Y, Watanabe M, Murata M, et al. Impact of genetic polymorphisms of 17-hydroxylase cytochrome p-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 2001;92:683-6. 55. Febbo PG, Kantoff PW, Platz EA, et al. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res 1999;59:5878-81. 56. Jaffe JM, Malkowicz SB, Walker AH, et al. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 2000;60:1626-30. 57. Hsing AW, Chen C, Chokkalingam AP, et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidem Biomar 2001;10:1077-82. 58. Pearce CL, Makridakis NM, Ross RK, et al. Steroid 5-α reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidem Biomar 2002;11:417-18. 59. Chang BL, Zheng SL, Isaacs SD, et al. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer. The Prostate 2003;56:37-44. 60. Bioinforamatic harvester. Stanford University Web Site. Available at:http://genome-www5.stanford.edu/cgi-bin/source [Accessed 24 May 2006]. 61. Human prostate gene database. Available at:http://CYP17 – cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia.mht [Accessed 24 May 2006]. 62. Morimoto LM, White E, Newcomb PA. Selection bias in the assessment of gene-environmental interaction in case-control studies. Am J Epidemiol 2003;158:259-63. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31619 | - |
| dc.description.abstract | 背景：肺癌是台灣癌症的首要死因，本研究探討睪固酮生成和代謝相關基因的基因多形性與台灣男性肺腺癌危險性的相關，包括：CYP17、SRD5A2 和 AR-CAG 重複序列數目的多形性。
方法：本研究是一病例對照研究，自2002年9月至2004年3月，以頻率配對方式選取來自台灣6個醫學中心的男性肺腺癌病例共357名與各醫院健檢中心的健康對照357名。受試者接受問卷訪視和提供血液樣本，以毛細管電泳和TaqMan 即時聚合酵素連鎖反應為基礎的方式分析AR-CAG 重複序列數目和CYP17及SRD5A2 基因的多形性。各基因多形性的危險對比值和95%信賴區間以非條件式羅吉斯迴歸模式進行分析。 結果：調整年齡、教育年數、香菸暴露（吸菸和二手菸暴露）、父親肺癌病史和曾經得過結核病等因子後，CPY17 A1/A1基因型相對於A2/A2和A2/A1基因型有1.46倍的危險性 (95%信賴區間=0.85-2.47)；SRD5A2 Val/Val基因型相對於Val/Leu和Leu/Leu基因型有1.79倍的危險性 (95%信賴區間=1.03-3.10 )；至於AR-CAG 重複序列數目的多形性和肺腺癌，則無相關。 結論：本研究發現睪固酮生成和代謝相關基因CPY17 A1/A1和SRD5A2 Val/Val多形性和男性肺腺癌的發生有關。 | zh_TW |
| dc.description.abstract | Background: Lung cancer is the leading cause of cancer death in Taiwan. This study aimed to investigate the association of male lung adenocarcinoma and polymorphism of testosterone biosynthetic and metabolic pathway-related genes, including CYP17 and SRD5A2, and the number of CAG repeat length in the androgen receptor (AG) gene.
Methods: A total of 357 male patients with lung adenocarcinoma and 357 healthy hospital controls selected by frequency matching were recruited at 6 medical centers in Taiwan from September 2002 to August 2004. These subjects had been interviewed by questionnaires and provided blood samples for analysis. The number of CAG repeat length in the AR gene and genetic polymorphisms of cytochrome17α (CYP17) and 5α-reductase type II (SRD5A2) were determined by capillary electrophoresis and TaqMan assays. Unconditional multivariate logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for each genotype. Results: After having adjusted for age, schooling year, cigarette smoking exposure, father with lung cancer, and tuberculosis, the ORs of developing lung adenocarcinoma were 1.46 (95% CI=0.85-2.47) for CYP17 A1/A1 genotype compared with A2/A2 and A2/A1 genotype and 1.79 (95% CI=1.03-3.10) for SRD5A2 Val/Val compared with Val/Leu and Leu/Leu genotypes. For AR-CAG repeats length, there was no any association with lung adenocarcinoma. Conclusion: Our result suggest that testosterone-related gene polymorphisms including CYP17 A1/A1 and SRD5A2 Val/Val might contribute to male lung adenocarcinoma in Taiwan. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T03:15:59Z (GMT). No. of bitstreams: 1 ntu-95-R92846018-1.pdf: 4502952 bytes, checksum: 9005e0547373e275a1ad37e24065aafb (MD5) Previous issue date: 2006 | en |
| dc.description.tableofcontents | Contents
Contents I Chinese Abstract 1 English Abstract 2 Chapter 1. Review of the Literature 3 1.1 Risk factors 4 1.2 Number of CAG repeat length in the AR gene 6 1.3 CYP17 gene polymorphisms 8 1.4 SRD5A2 gene polymorphisms 9 Chapter 2. Materials and Methods 11 2.1 Study subjects 11 2.2 Blood collection and DNA extraction 12 2.3 Analysis for the number of CAG repeat length in the AR gene 12 2.4 Genotyping 13 2.5 Statistical analysis 14 Chapter 3. Results 16 3.1 Demographic characteristics of study subjects 16 3.2 Ambient air pollution exposure of study subjects 16 3.3 Disease status of study subjects 17 3.4 Number of CAG repeat length in the AR gene 18 3.5 SNPs of testosterone biosynthetic and metabolic pathway-related genes 19 3.6 Genetic markers and environmental factor interaction 20 Chapter 4. Discussion 22 References 28 Contents of Tables Table 1.1 Summary of previous studies on associations between AR and prostate cancer risk 37 Table 1.2 Summary of the previous studies on associations between CYP17 and prostate cancer risk 39 Table 1.3 Summary of the previous studies on associations between SRD5A2 and prostate cancer risk 42 Table 2.1 Sequence of primer and probe sets for using TaqMan Technique 48 Table 3.1 Demographic characteristics of study subjects 49 Table 3.2 ORs and 95% CIs of cigarette smoking exposure for developing male lung adenocarcinoma 50 Table 3.3 ORs and 95% CIs of disease status for developing male lung adenocarcinoma among subjects and parents 52 Table 3.4 Distribution of the number of CAG repeat length in the AR gene and ORs and 95% CIs for developing male lung adenocarcinoma 53 Table 3.5 ORs and 95% CIs of SNPs of testosterone biosynthesis and metabolism pathway-related genes for developing male lung adenocarcinoma 54 Table 3.6 Gene-gene interaction between CYP17 and SRD5A2 for developing male lung adenocarcinoma 56 Table 3.7 ORs and 95% CIs of combined cigarette smoking exposure and SNPs of CYP17 and SRD5A2 genes for developing male lung adenocarcinoma 57 Contents of Figures Figure 1.1 Biosynthesis and metabolism pathway of androgen 59 Appendix Questionnaire for risk factors of male lung adenocarcinoma in genetic epidemiological study of pulmonary disease in Taiwan 60 | |
| dc.language.iso | en | |
| dc.subject | 男性肺腺癌 | zh_TW |
| dc.subject | 台灣 | zh_TW |
| dc.subject | 流行病學研究 | zh_TW |
| dc.subject | 睪固酮相關基因 | zh_TW |
| dc.subject | 基因多形性 | zh_TW |
| dc.subject | male lung adenocarcinoma | en |
| dc.subject | testosterone-related genes | en |
| dc.subject | epidemiological study | en |
| dc.subject | Taiwan | en |
| dc.subject | genetic polymorphism | en |
| dc.title | 台灣男性肺腺癌與睪固酮相關基因多形性之基因體流行病學研究 | zh_TW |
| dc.title | Genetic Epidemiological Study on Association between Polymorphisms in Testosterone-Related Genes and Risk of Male Lung Adenocarcinoma in Taiwan | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 94-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 郭壽雄,張基晟 | |
| dc.subject.keyword | 男性肺腺癌,基因多形性,睪固酮相關基因,流行病學研究,台灣, | zh_TW |
| dc.subject.keyword | male lung adenocarcinoma,genetic polymorphism,testosterone-related genes,epidemiological study,Taiwan, | en |
| dc.relation.page | 70 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2006-07-31 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 預防醫學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-95-1.pdf 未授權公開取用 | 4.4 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。